Search Results
Jun 02, 2026, 09:00 ET The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
determinations — a reminder that reimbursement policy, not science, can dominate a tissue company's year. [6]MiMedx Group, Inc. (NASDAQ: MDXG), which makes regenerative biologics from placental tissue, hit the same wall. On April 29 it reported first-quarter net sales of $59 million, down
More news about: Equity Insider
May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 14, 2026, 23:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP